Latest Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence in patients with early breast cancer; supports regulatory submissions December 11, 2023
Inavolisib combination reduces the risk of disease progression by 57% in people with advanced HR+ve, HER2-neg breast cancer with a PIK3CA mutation December 11, 2023
Kadcyla shows significant OS benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment December 11, 2023
Findings from Ph 2 KeyVibe-002 Trial of Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with mNSCLC Announced December 11, 2023
New Positive Interim Data from Dose Escalation and Ph 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients Announced December 11, 2023
New Data Show Durable Response Following Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg) December 11, 2023
Successful Completion and Interim Results of Ph 1 Study of HC-5404 in Solid Tumors announced December 11, 2023
Data from Ph 1/2 APEX-01 Dose Escalation Study of ARX517 in metastatic CRPC announced December 11, 2023
Positive results from DREAMM-7 head-to-head Ph 3 trial for Blenrep in R/R multiple myeloma announced December 4, 2023
New Preliminary OS data in Selinexor-Treated Patients with Advanced or Recurrent TP53 WT Endometrial Cancer from the SIENDO Study Announced December 4, 2023
Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population Announced December 4, 2023
Imfinzi + Avastin met primary endpoint for PFS in liver cancer eligible for embolisation in EMERALD-1 Ph 3 trial December 4, 2023
KEYTRUDA Significantly Improved OS Versus Placebo as Adjuvant Therapy for Certain Patients With RCC Following Nephrectomy November 7, 2023
Ph 3 RUBY trial of Jemperli + chemotherapy meets OS endpoint in patients with primary advanced or recurrent endometrial cancer November 7, 2023
Ph 3 CheckMate-67T Trial of SC Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced/Metastatic ccRCC October 25, 2023
New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study Released October 25, 2023
Interim PK/PD and Clinical Data for MRT-2359 in Ph 1/2 Trial for MYC-Driven Solid Tumors announced October 25, 2023
New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized 1L HCC Study presented October 16, 2023
Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of OS in Resectable Stage II, IIIA or IIIB NSCLC October 16, 2023
Updated PC14586 Ph 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation October 16, 2023
Interim Results from Ph 2 Trial of IT LSAM-PTX in Locally Advanced Pancreatic Cancer Patients Announced October 16, 2023
